{"gene":"NFE2","run_date":"2026-04-29T11:37:56","timeline":{"discoveries":[{"year":1993,"finding":"NFE2 (p45 NF-E2) is a hematopoietic-specific basic-leucine zipper protein that dimerizes with a ubiquitous partner (p18) to form the functional NF-E2 heterodimer, which binds AP-1-like recognition sites in globin locus control regions.","method":"cDNA cloning, protein purification, DNA binding assays","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1 — original cloning with biochemical characterization, foundational paper with 598 citations","pmids":["8469283"],"is_preprint":false},{"year":1993,"finding":"The ubiquitous p18 subunit of NF-E2 is a small basic-leucine zipper protein related to the v-maf oncogene, and forms the obligate heterodimeric partner with p45 NF-E2 for DNA binding.","method":"Protein purification, cDNA cloning, sequence analysis","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 — protein purification and cloning with 250 citations, replicated by other labs","pmids":["8265578"],"is_preprint":false},{"year":1994,"finding":"Small Maf proteins (MafF, MafG, MafK) directly control the DNA-binding properties of p45 NF-E2 through heterodimeric association; Maf homodimers act as negative regulators while p45-Maf heterodimers support active transcription, establishing that small Maf proteins are the second constituent chain of NF-E2.","method":"In vitro dimerization assays, transcription assays in erythroid cells, transfection experiments","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1 — reconstituted heterodimer activity in vitro and in vivo, replicated across labs, 417 citations","pmids":["8107826"],"is_preprint":false},{"year":1993,"finding":"NF-E2 binding to AP-1/NF-E2 sites in the beta-globin locus control region enhancer is required for enhancer-dependent transcription of epsilon-globin, while GATA-1 binding at the promoter mediates the enhancer-promoter interaction.","method":"In vitro transcription, site-directed mutagenesis of NF-E2 sites","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1 — in vitro transcription with mutagenesis, multiple orthogonal approaches","pmids":["8423810"],"is_preprint":false},{"year":1995,"finding":"Small Maf proteins can also heterodimerize with Fos, and Fos-small Maf heterodimers cannot activate NF-E2 site-dependent transcription, suggesting competitive regulation of erythroid gene expression among Fos, NF-E2 p45, and small Maf proteins.","method":"In vitro DNA binding, co-immunoprecipitation, transfection assays","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1 — multiple in vitro and in vivo assays, replicated interaction data","pmids":["7891713"],"is_preprint":false},{"year":1996,"finding":"Bach1 and Bach2, novel BTB-bZip transcription factors, heterodimerize with MafK and bind NF-E2 sites in vitro; they function as transcriptional repressors in fibroblasts but Bach1 acts as an activator in erythroid cells, competing with p45 NF-E2 for MafK binding.","method":"Yeast two-hybrid screen, in vitro DNA binding, transfection assays","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1–2 — yeast two-hybrid plus in vitro binding plus functional assays, 567 citations","pmids":["8887638"],"is_preprint":false},{"year":1997,"finding":"p45 NF-E2 directly regulates the thromboxane synthase (TXS) gene in megakaryocytes through functional NF-E2 binding sites in its promoter and an intronic chromatin-dependent enhancer; p45-null megakaryocytes lack TXS mRNA.","method":"In vivo chromatin immunoprecipitation/immunoselection, promoter/enhancer reporter assays, p45-null mouse analysis","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 1–2 — in vivo binding plus reporter assays plus genetic knockout validation","pmids":["9312024"],"is_preprint":false},{"year":1998,"finding":"In primary megakaryocytes, p45 NF-E2 is the only large subunit that dimerizes with small Maf proteins; MafG and/or MafF predominate in megakaryocytes (unlike MafK in erythroid cells), and the NF-E2 complex preferentially binds an asymmetric AP-1-related motif.","method":"Nuclear extract preparation, EMSA, biochemical characterization of primary megakaryocytes","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1–2 — biochemical analysis of primary cells with multiple binding assays","pmids":["9516460"],"is_preprint":false},{"year":1998,"finding":"NF-E2 activity (both DNA binding and transactivation) is upregulated during erythroid differentiation in erythroleukemia cells via serine/threonine phosphorylation through the Ras-Raf-MAP kinase cascade; MafK homodimers suppress transcription by direct inhibition in addition to DNA site competition.","method":"Kinase inhibitor experiments, domain analysis, transient transfection assays, DMSO-induced differentiation","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 — functional assays with pharmacological inhibitors, single lab","pmids":["9478996"],"is_preprint":false},{"year":1999,"finding":"NF-E2-deficient megakaryocytes fail to activate alphaIIbbeta3 integrin in response to agonists despite normal surface expression, establishing that NF-E2 controls signaling pathways required for integrin activation that mature late in megakaryocyte development.","method":"Primary megakaryocytes from NF-E2 knockout mice, fibrinogen binding assays, Sindbis virus-mediated gene expression","journal":"The Journal of cell biology","confidence":"High","confidence_rationale":"Tier 2 — genetic knockout with specific phenotypic readout and complementation, replicated with pharmacological tools","pmids":["10613901"],"is_preprint":false},{"year":1999,"finding":"Mice lacking p45 NF-E2 have profound thrombocytopenia due to late arrest in megakaryocyte differentiation with reduced proliferation potential, and also develop erythroid abnormalities including anisocytosis, hypochromia, and small red blood cell fragments, establishing NF-E2 as required for both megakaryocyte and erythrocyte maturation.","method":"NF-E2 knockout mice, splenectomy, bone marrow transplantation, hematopoietic cell transfer","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 — multiple genetic and transplantation experiments with defined phenotypic readouts","pmids":["10556187"],"is_preprint":false},{"year":2000,"finding":"NF-E2 binds directly and specifically to the tandem Maf recognition elements of hypersensitive site 2 (HS2) of the beta-globin locus control region in living erythroleukemia cells and fetal liver, dependent on p45 and intact MAREs.","method":"Chromatin immunoprecipitation assay in intact cells","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 — ChIP in primary cells and cell lines with p45-null controls","pmids":["10891470"],"is_preprint":false},{"year":2000,"finding":"NF-E2 transcriptionally regulates beta1 tubulin expression in megakaryocytes; NF-E2-deficient megakaryocytes lack beta1 tubulin mRNA/protein, and restoring NF-E2 rescues beta1 tubulin expression, linking NF-E2 to microtubule-based proplatelet formation.","method":"mRNA subtraction between NF-E2-null and wild-type megakaryocytes, NF-E2 rescue experiments in primary cells and cell lines","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 — genetic loss-of-function with target gene identification and rescue, 133 citations","pmids":["10942379"],"is_preprint":false},{"year":2001,"finding":"CBP acetyltransferase physically interacts with both p45 NF-E2 and MafG subunits; CBP acetylates MafG predominantly in the basic region, and MafG acetylation augments NF-E2 DNA binding activity; mutations at major acetylation sites markedly reduce DNA binding and transcriptional activation.","method":"Co-immunoprecipitation in vitro and in vivo, acetyltransferase assays, mutagenesis, transfection reporter assays","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — in vitro enzymatic assay with mutagenesis and in vivo validation","pmids":["11154691"],"is_preprint":false},{"year":2001,"finding":"Human ITCH protein interacts with p45 NF-E2 (identified by yeast two-hybrid) and functions as a transcriptional corepressor of NF-E2 in transfection experiments.","method":"Yeast two-hybrid, transfection corepressor assays","journal":"Genomics","confidence":"Medium","confidence_rationale":"Tier 3 — yeast two-hybrid plus transfection assay, single lab, limited follow-up","pmids":["11318614"],"is_preprint":false},{"year":2003,"finding":"NF-E2 transcriptionally regulates Rab27b expression in megakaryocytes; ChIP demonstrates NF-E2 recruitment to the Rab27B promoter; Rab27b localizes to alpha and dense granules, and inhibition of Rab27 function causes severe defects in proplatelet formation.","method":"Chromatin immunoprecipitation, subcellular localization (immunofluorescence), dominant-negative inhibition in primary megakaryocytes","journal":"Blood","confidence":"High","confidence_rationale":"Tier 1–2 — ChIP plus localization plus functional assay in primary cells","pmids":["12907454"],"is_preprint":false},{"year":2004,"finding":"Heme induces displacement of Bach1 from MafK-occupied ho-1 enhancers and subsequent Nrf2 binding, accompanied by de novo histone H3 hyperacetylation and hypermethylation in the transcribed region, establishing heme as a signaling molecule that drives partner exchange in the small Maf transcription factor network.","method":"Chromatin immunoprecipitation assays in NIH 3T3 cells, histone modification analysis","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1–2 — ChIP with multiple histone marks, replicated at both ho-1 and beta-globin loci, 311 citations","pmids":["14747657"],"is_preprint":false},{"year":2007,"finding":"In differentiating erythroid cells, formation of the beta-globin active chromatin hub (ACH) requires GATA-1 and EKLF but not p45 NF-E2; NF-E2 is dispensable for ACH formation as shown in p45 NF-E2 knockout mice.","method":"Chromosome conformation capture (3C), knock-out mouse analysis, erythroid differentiation model","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 — genetic knockout with specific chromatin structure readout using 3C","pmids":["17428799"],"is_preprint":false},{"year":2009,"finding":"In megakaryocytes, p45 NF-E2 dominates over Nrf2 at shared cytoprotective gene targets, acting as a less efficacious activator to maintain moderate expression, thereby promoting ROS accumulation that in turn enhances platelet gene expression and megakaryocytic maturation.","method":"Comprehensive gene expression profiling in wild-type and p45-null megakaryocytes, competition assays between p45 and Nrf2","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 — genome-wide expression profiling with genetic null models plus functional follow-up","pmids":["19901266"],"is_preprint":false},{"year":2010,"finding":"AML1/RUNX1 directly binds the NF-E2 promoter in vivo and transcriptionally activates NF-E2 expression; AML1 binding is increased in granulocytes from polycythemia vera patients; RNAi knockdown of AML1 or its partner CBF-beta decreases NF-E2 expression, identifying NF-E2 as a novel AML1 target gene.","method":"Chromatin immunoprecipitation, RNAi knockdown, promoter characterization, NF-E2 promoter-reporter assays","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 — ChIP in primary patient cells plus RNAi with multiple approaches","pmids":["20339092"],"is_preprint":false},{"year":2012,"finding":"Overexpression of NF-E2 in hematopoietic cells causes myeloproliferative neoplasm features including thrombocytosis and leukocytosis; NF-E2 transgenic mice show hypoacetylation of histone H3, and HDAC inhibitor treatment restores H3 acetylation, decreases NF-E2 expression, and normalizes platelet numbers.","method":"NF-E2 transgenic mouse model, bone marrow transplantation, histone modification analysis, HDAC inhibitor treatment","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 2 — transgenic mouse model with transplantation and pharmacological rescue, 71 citations","pmids":["22231305"],"is_preprint":false},{"year":2013,"finding":"Acquired truncating insertion/deletion mutations in NFE2 found in MPN patients produce truncated NF-E2 proteins that enhance wild-type NF-E2 function; expression in mice causes erythrocytosis and thrombocytosis, and mutant cells acquire clonal dominance over wild-type NF-E2 cells.","method":"Mutation sequencing in MPN patients, murine model of mutant NFE2 expression, clonal analysis","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 2 — human mutations functionally characterized in murine model with clonal analysis","pmids":["23589569"],"is_preprint":false},{"year":2016,"finding":"NF-E2 co-occupies late-acting cis-regulatory enhancers with FLI1 and RUNX1 in terminal megakaryocyte maturation; co-occupancy by NF-E2 with either RUNX1 or FLI1 gives the highest H3K4me2 histone signals and correlates with genes activated late in megakaryocyte differentiation responsible for platelet assembly and release.","method":"ChIP-seq for NF-E2, FLI1, RUNX1, and histone marks; genome-wide chromatin dynamics analysis in primary megakaryocytes","journal":"Scientific reports","confidence":"High","confidence_rationale":"Tier 2 — genome-wide ChIP-seq in primary cells with genetic validation using Nfe2-null","pmids":["27457419"],"is_preprint":false},{"year":2017,"finding":"NFE2 directly induces miR-423-5p expression to repress the FAM3A-ATP-Akt pathway in hepatocytes, promoting gluconeogenesis, lipid deposition, and hyperglycemia; hepatic NFE2 overexpression phenocopies this pathway activation in normal mice.","method":"miRNA target validation, reporter assays, NFE2 overexpression in mouse liver, siRNA knockdown","journal":"Diabetes","confidence":"Medium","confidence_rationale":"Tier 2 — in vivo overexpression with mechanistic pathway tracing, single lab","pmids":["28411267"],"is_preprint":false},{"year":2018,"finding":"Histone demethylase JMJD1C is a novel NFE2 target gene; JMJD1C in turn binds the NFE2 promoter, decreasing H3K9me2 levels and HP1α binding to autoregulate NFE2 expression; separately, JAK2V617F-driven H3Y41 phosphorylation also inhibits HP1α binding to activate NFE2 expression.","method":"ChIP at JMJD1C and NFE2 promoters, histone modification analysis, decitabine treatment in JAK2V617F cell lines","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 — ChIP with multiple histone marks plus pharmacological and genetic perturbation, replicated in patient samples","pmids":["29519804"],"is_preprint":false},{"year":2019,"finding":"NFE2 mutations in AML patients and in MPN patients predispose to leukemic transformation; NF-E2 mutant mice develop myelosarcomas and AML acquiring secondary mutations including trisomy 8 equivalent, chromosome 5q deletions, and Trp53 mutations.","method":"Longitudinal mouse modeling of NFE2 mutations, cytogenetic and mutation analysis of transformed tumors","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 — in vivo mouse model with defined secondary lesions, validated in human AML samples","pmids":["30755419"],"is_preprint":false},{"year":1995,"finding":"Two alternatively spliced isoforms of NF-E2 (aNF-E2 and fNF-E2) differ in their 5' untranslated regions and are expressed in different ratios during development (fNF-E2 predominates in fetal liver; aNF-E2 in adult bone marrow), though both produce the same protein.","method":"cDNA library screening, RT-PCR, developmental expression analysis","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"Medium","confidence_rationale":"Tier 3 — cloning and expression pattern, single lab","pmids":["7724591"],"is_preprint":false},{"year":2003,"finding":"Mice deficient in NF-E2 (or GATA-1) show 200–300% increases in bone volume and formation; osteoblast proliferation increases up to 6-fold when cultured with NF-E2-deficient megakaryocytes by a mechanism requiring cell-to-cell contact, revealing a megakaryocyte-osteoblast interaction dependent on the excess immature megakaryocytes produced in NF-E2 null mice.","method":"Histomorphometry, microCT, in vitro co-culture of osteoblasts with NF-E2-null megakaryocytes","journal":"Journal of bone and mineral research","confidence":"Medium","confidence_rationale":"Tier 2 — genetic model with in vitro co-culture phenotype, but mechanistic details indirect","pmids":["15005853"],"is_preprint":false},{"year":2014,"finding":"Rho kinase (ROCK) inhibition drives megakaryocyte polyploidization and proplatelet formation, coinciding with downregulation of NFE2 expression in mature megakaryocytes, suggesting a model where ROCK inhibition drives late megakaryocyte maturation through NFE2 downregulation.","method":"ROCK inhibitor treatment of cord blood-derived megakaryocytes, proplatelet formation assay, gene expression analysis","journal":"British journal of haematology","confidence":"Low","confidence_rationale":"Tier 3 — pharmacological inhibitor study with correlative NFE2 expression change, no direct NFE2 rescue","pmids":["24383889"],"is_preprint":false}],"current_model":"NFE2 (p45 NF-E2) is a hematopoietic-specific CNC-family basic-leucine zipper transcription factor that forms obligate heterodimers with small Maf proteins (MafF/G/K) — whose DNA-binding activity is augmented by CBP-mediated acetylation of MafG — to bind NF-E2/AP-1-like sites in the locus control regions of globin genes and in promoters/enhancers of megakaryocyte genes including thromboxane synthase, beta1 tubulin, and Rab27b, thereby driving erythroid differentiation and being essential for proplatelet formation and platelet biogenesis; NFE2 activity is co-regulated by competing partners (Bach1, Fos-Maf) and upstream regulators including AML1/RUNX1 (which drives NFE2 transcription) and JMJD1C (which participates in an NFE2 autoregulatory loop via H3K9 demethylation), and overexpression or gain-of-function mutations in NFE2 cause myeloproliferative neoplasms with predisposition to leukemic transformation."},"narrative":{"teleology":[{"year":1993,"claim":"Identification of NFE2 as a hematopoietic bZIP factor that heterodimerizes with a small subunit to bind AP-1-like sites in globin LCRs established the molecular identity of the NF-E2 complex and its role in erythroid gene regulation.","evidence":"cDNA cloning, protein purification, DNA-binding assays, and in vitro transcription with NF-E2-site mutagenesis","pmids":["8469283","8265578","8423810"],"confidence":"High","gaps":["Identity of the small subunit not yet resolved as Maf family","In vivo target gene specificity unknown"]},{"year":1994,"claim":"Demonstrating that small Maf proteins (MafF/G/K) are the obligate heterodimeric partners of p45 resolved the composition of functional NF-E2 and revealed that Maf homodimers act as repressors, establishing a competitive dimerization paradigm.","evidence":"In vitro dimerization and transcription assays in erythroid cells","pmids":["8107826"],"confidence":"High","gaps":["Relative contributions of individual small Mafs in different lineages unknown","In vivo stoichiometry unresolved"]},{"year":1996,"claim":"Discovery that Bach1, Fos, and other bZIP factors compete with p45 for small Maf binding at NF-E2 sites established a partner-exchange regulatory network controlling erythroid and stress-response gene expression.","evidence":"Yeast two-hybrid, in vitro DNA binding, transfection assays, and later heme-induced ChIP showing Bach1 displacement","pmids":["7891713","8887638","14747657"],"confidence":"High","gaps":["Relative affinities and kinetics of partner exchange in vivo not quantified","Signals governing Bach1–NF-E2 switching beyond heme not fully defined"]},{"year":1999,"claim":"Analysis of NF-E2-knockout mice revealed that p45 is essential for platelet biogenesis and erythrocyte maturation, with thrombocytopenia resulting from a late block in megakaryocyte differentiation and failure of integrin αIIbβ3 activation.","evidence":"NF-E2-null mice with bone marrow transplantation, fibrinogen binding, and complementation assays","pmids":["10556187","10613901"],"confidence":"High","gaps":["Full repertoire of NF-E2-dependent megakaryocyte genes not catalogued","Mechanism of integrin activation defect unclear"]},{"year":2000,"claim":"Identification of β1 tubulin and confirmation of NF-E2 occupancy at the β-globin LCR HS2 in living cells defined direct transcriptional targets linking NF-E2 to cytoskeletal proplatelet formation and globin regulation.","evidence":"ChIP in erythroleukemia and fetal liver cells; mRNA subtraction between NF-E2-null and WT megakaryocytes with rescue","pmids":["10891470","10942379"],"confidence":"High","gaps":["Whether NF-E2 is required for LCR-mediated chromatin looping not resolved"]},{"year":2001,"claim":"CBP-mediated acetylation of MafG in its basic region augments NF-E2 DNA binding and transactivation, establishing post-translational modification of the heterodimeric partner as a regulatory mechanism.","evidence":"In vitro acetyltransferase assays, co-immunoprecipitation, mutagenesis, transfection reporter assays","pmids":["11154691"],"confidence":"High","gaps":["In vivo dynamics of MafG acetylation during differentiation unknown","Other acetyltransferases not tested"]},{"year":2003,"claim":"NF-E2 directly activates Rab27b in megakaryocytes, linking NF-E2 to granule transport and proplatelet formation through a vesicle-trafficking effector.","evidence":"ChIP at Rab27b promoter, immunofluorescence localization, dominant-negative Rab27 inhibition in primary megakaryocytes","pmids":["12907454"],"confidence":"High","gaps":["Full set of granule-trafficking genes controlled by NF-E2 not defined"]},{"year":2007,"claim":"Chromosome conformation capture in NF-E2-null erythroid cells demonstrated that NF-E2 is dispensable for β-globin active chromatin hub formation, refining NF-E2's role to transcriptional activation rather than long-range chromatin looping.","evidence":"3C assays in NF-E2-knockout mouse erythroid cells","pmids":["17428799"],"confidence":"High","gaps":["Precise step at which NF-E2 acts after chromatin hub assembly not defined"]},{"year":2010,"claim":"Identifying NFE2 as a direct transcriptional target of AML1/RUNX1 placed NFE2 downstream of a key megakaryocyte master regulator and explained elevated NFE2 in polycythemia vera.","evidence":"ChIP at NFE2 promoter, RNAi knockdown of AML1/CBFβ, promoter-reporter assays in patient granulocytes","pmids":["20339092"],"confidence":"High","gaps":["Whether RUNX1-driven NFE2 upregulation is sufficient for MPN initiation not tested"]},{"year":2012,"claim":"Transgenic overexpression of NF-E2 caused myeloproliferative neoplasm features with histone H3 hypoacetylation, reversible by HDAC inhibitors, establishing NFE2 gain-of-function as oncogenic in myeloid neoplasia.","evidence":"NF-E2 transgenic mouse model, bone marrow transplantation, histone modification analysis, HDAC inhibitor rescue","pmids":["22231305"],"confidence":"High","gaps":["Direct chromatin targets mediating the MPN phenotype not identified"]},{"year":2013,"claim":"Acquired truncating NFE2 mutations in MPN patients produce gain-of-function proteins that enhance wild-type NF-E2 activity and confer clonal dominance, providing a genetic mechanism for disease progression.","evidence":"Patient mutation sequencing, murine expression model, clonal competition assays","pmids":["23589569"],"confidence":"High","gaps":["Structural basis for gain-of-function by truncated proteins unknown"]},{"year":2016,"claim":"Genome-wide co-occupancy mapping showed NF-E2 collaborates with FLI1 and RUNX1 at late-acting megakaryocyte enhancers marked by high H3K4me2, defining the combinatorial code for terminal platelet gene activation.","evidence":"ChIP-seq for NF-E2, FLI1, RUNX1, and histone marks in primary megakaryocytes","pmids":["27457419"],"confidence":"High","gaps":["Causal hierarchy among NF-E2, FLI1, and RUNX1 at co-occupied enhancers not resolved"]},{"year":2018,"claim":"Discovery of a JMJD1C–NFE2 autoregulatory loop, where NFE2 induces JMJD1C which demethylates H3K9 at the NFE2 promoter to sustain NFE2 expression, revealed an epigenetic feedforward mechanism exploited by JAK2V617F-driven MPN.","evidence":"ChIP at JMJD1C and NFE2 promoters, histone modification analysis, pharmacological perturbation in JAK2V617F cells and patient samples","pmids":["29519804"],"confidence":"High","gaps":["Whether disrupting the JMJD1C–NFE2 loop is therapeutically sufficient in MPN is untested"]},{"year":2019,"claim":"Longitudinal modeling showed NFE2 mutations predispose to AML transformation with acquisition of secondary lesions including Trp53 loss and trisomy 8 equivalent, establishing NFE2 as a driver of leukemic evolution.","evidence":"Mouse modeling of NFE2 mutations with cytogenetic and mutation analysis of transformed tumors, validated in human AML","pmids":["30755419"],"confidence":"High","gaps":["Whether NFE2 mutations directly cause genomic instability or simply provide a selective advantage is unresolved"]},{"year":null,"claim":"The structural basis for how truncated NFE2 mutant proteins enhance wild-type function, the full catalog of direct NF-E2 target genes in megakaryocytes versus erythroid cells, and whether targeting the JMJD1C–NFE2 autoregulatory loop can prevent leukemic transformation remain open questions.","evidence":"","pmids":[],"confidence":"Low","gaps":["No crystal structure of NF-E2–Maf heterodimer available","Genome-wide NF-E2 target gene sets in erythroid cells not comprehensively validated","Therapeutic strategies targeting NFE2 overexpression in MPN not clinically tested"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[0,3,11]},{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[0,3,6,12,15,22]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[0,7,11]}],"pathway":[{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[0,3,6,12,15,22]},{"term_id":"R-HSA-4839726","term_label":"Chromatin organization","supporting_discovery_ids":[13,16,24]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[10,12,22]},{"term_id":"R-HSA-109582","term_label":"Hemostasis","supporting_discovery_ids":[9,10,12]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[20,21,25]}],"complexes":["NF-E2 (p45-small Maf heterodimer)"],"partners":["MAFF","MAFG","MAFK","BACH1","CREBBP","FLI1","RUNX1","JMJD1C"],"other_free_text":[]},"mechanistic_narrative":"NFE2 (p45 NF-E2) is a hematopoietic-specific CNC-family basic-leucine zipper transcription factor essential for terminal megakaryocyte maturation, proplatelet formation, and erythroid differentiation. It forms obligate heterodimers with small Maf proteins (MafF, MafG, MafK) to bind NF-E2/AP-1-like recognition elements in globin locus control regions and in megakaryocyte-specific gene promoters including thromboxane synthase, β1 tubulin, and Rab27b, with DNA-binding activity augmented by CBP-mediated acetylation of MafG [PMID:8469283, PMID:8107826, PMID:11154691, PMID:9312024, PMID:10942379, PMID:12907454]. NFE2 activity is regulated by competing partners (Bach1, Fos–Maf homodimers) for small Maf binding, by upstream transcriptional activation through AML1/RUNX1, and by an autoregulatory loop involving the histone demethylase JMJD1C that modulates H3K9 methylation at the NFE2 promoter [PMID:8887638, PMID:7891713, PMID:20339092, PMID:29519804]. Overexpression or acquired truncating mutations of NFE2 cause myeloproliferative neoplasms with thrombocytosis and predisposition to leukemic transformation [PMID:22231305, PMID:23589569, PMID:30755419]."},"prefetch_data":{"uniprot":{"accession":"Q16621","full_name":"Transcription factor NF-E2 45 kDa subunit","aliases":["Leucine zipper protein NF-E2","Nuclear factor, erythroid-derived 2 45 kDa subunit","p45 NF-E2"],"length_aa":373,"mass_kda":41.5,"function":"Component of the NF-E2 complex essential for regulating erythroid and megakaryocytic maturation and differentiation. Binds to the hypersensitive site 2 (HS2) of the beta-globin control region (LCR). This subunit (NFE2) recognizes the TCAT/C sequence of the AP-1-like core palindrome present in a number of erythroid and megakaryocytic gene promoters. Requires MAFK or other small MAF proteins for binding to the NF-E2 motif. May play a role in all aspects of hemoglobin production from globin and heme synthesis to procurement of iron","subcellular_location":"Nucleus, PML body; Cytoplasm","url":"https://www.uniprot.org/uniprotkb/Q16621/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/NFE2","classification":"Not Classified","n_dependent_lines":20,"n_total_lines":1208,"dependency_fraction":0.016556291390728478},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/NFE2","total_profiled":1310},"omim":[{"mim_id":"612133","title":"TRANSCRIPTION FACTOR NFE4; NFE4","url":"https://www.omim.org/entry/612133"},{"mim_id":"608537","title":"VON HIPPEL-LINDAU TUMOR SUPPRESSOR; VHL","url":"https://www.omim.org/entry/608537"},{"mim_id":"606834","title":"LYSINE-SPECIFIC METHYLTRANSFERASE 2B; KMT2B","url":"https://www.omim.org/entry/606834"},{"mim_id":"606409","title":"ITCHY E3 UBIQUITIN PROTEIN LIGASE; ITCH","url":"https://www.omim.org/entry/606409"},{"mim_id":"604135","title":"NUCLEAR FACTOR ERYTHROID 2-LIKE 3; NFE2L3","url":"https://www.omim.org/entry/604135"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Nucleoplasm","reliability":"Approved"},{"location":"Actin filaments","reliability":"Approved"}],"tissue_specificity":"Group enriched","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"bone marrow","ntpm":106.1},{"tissue":"lymphoid tissue","ntpm":45.9}],"url":"https://www.proteinatlas.org/search/NFE2"},"hgnc":{"alias_symbol":["NF-E2"],"prev_symbol":[]},"alphafold":{"accession":"Q16621","domains":[{"cath_id":"1.10.880.10","chopping":"224-316","consensus_level":"medium","plddt":97.3876,"start":224,"end":316}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q16621","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q16621-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q16621-F1-predicted_aligned_error_v6.png","plddt_mean":66.31},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=NFE2","jax_strain_url":"https://www.jax.org/strain/search?query=NFE2"},"sequence":{"accession":"Q16621","fasta_url":"https://rest.uniprot.org/uniprotkb/Q16621.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q16621/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q16621"}},"corpus_meta":[{"pmid":"8469283","id":"PMC_8469283","title":"Erythroid transcription factor NF-E2 is a haematopoietic-specific basic-leucine zipper protein.","date":"1993","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/8469283","citation_count":598,"is_preprint":false},{"pmid":"8887638","id":"PMC_8887638","title":"Bach proteins belong to a novel family of BTB-basic leucine zipper transcription factors that interact with MafK and regulate transcription through the NF-E2 site.","date":"1996","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/8887638","citation_count":567,"is_preprint":false},{"pmid":"8943040","id":"PMC_8943040","title":"NRF2, a member of the NFE2 family of transcription factors, is not essential for murine erythropoiesis, growth, and development.","date":"1996","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/8943040","citation_count":565,"is_preprint":false},{"pmid":"8107826","id":"PMC_8107826","title":"Regulation of transcription by dimerization of erythroid factor NF-E2 p45 with small Maf proteins.","date":"1994","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/8107826","citation_count":417,"is_preprint":false},{"pmid":"15882976","id":"PMC_15882976","title":"Resveratrol upregulates heme oxygenase-1 expression via activation of NF-E2-related factor 2 in PC12 cells.","date":"2005","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/15882976","citation_count":344,"is_preprint":false},{"pmid":"14747657","id":"PMC_14747657","title":"Heme regulates the dynamic exchange of Bach1 and NF-E2-related factors in the Maf transcription factor network.","date":"2004","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/14747657","citation_count":311,"is_preprint":false},{"pmid":"8248256","id":"PMC_8248256","title":"Cloning of Nrf1, an NF-E2-related transcription factor, by genetic selection in yeast.","date":"1993","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/8248256","citation_count":304,"is_preprint":false},{"pmid":"12842875","id":"PMC_12842875","title":"NF-E2-related factor-2 mediates neuroprotection against mitochondrial complex I inhibitors and increased concentrations of intracellular calcium in primary cortical neurons.","date":"2003","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12842875","citation_count":268,"is_preprint":false},{"pmid":"12700136","id":"PMC_12700136","title":"Atypical protein kinase C mediates activation of NF-E2-related factor 2 in response to oxidative stress.","date":"2003","source":"American journal of physiology. Cell physiology","url":"https://pubmed.ncbi.nlm.nih.gov/12700136","citation_count":267,"is_preprint":false},{"pmid":"8265578","id":"PMC_8265578","title":"The ubiquitous subunit of erythroid transcription factor NF-E2 is a small basic-leucine zipper protein related to the v-maf oncogene.","date":"1993","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/8265578","citation_count":250,"is_preprint":false},{"pmid":"18566336","id":"PMC_18566336","title":"Down-regulated NF-E2-related factor 2 in pulmonary macrophages of aged smokers and patients with chronic obstructive pulmonary disease.","date":"2008","source":"American journal of respiratory cell and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/18566336","citation_count":244,"is_preprint":false},{"pmid":"12391262","id":"PMC_12391262","title":"Phosphatidylinositol 3-kinase regulates nuclear translocation of NF-E2-related factor 2 through actin rearrangement in response to oxidative stress.","date":"2002","source":"Molecular pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/12391262","citation_count":244,"is_preprint":false},{"pmid":"18281592","id":"PMC_18281592","title":"NF-E2-related factor 2 inhibits lipid accumulation and oxidative stress in mice fed a high-fat diet.","date":"2008","source":"The Journal of pharmacology and experimental therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/18281592","citation_count":218,"is_preprint":false},{"pmid":"7891713","id":"PMC_7891713","title":"Small Maf proteins heterodimerize with Fos and may act as competitive repressors of the NF-E2 transcription factor.","date":"1995","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/7891713","citation_count":215,"is_preprint":false},{"pmid":"18633117","id":"PMC_18633117","title":"Activation of NF-E2-related factor-2 reverses biochemical dysfunction of endothelial cells induced by hyperglycemia linked to vascular disease.","date":"2008","source":"Diabetes","url":"https://pubmed.ncbi.nlm.nih.gov/18633117","citation_count":195,"is_preprint":false},{"pmid":"29552625","id":"PMC_29552625","title":"Experimental Nonalcoholic Steatohepatitis and Liver Fibrosis Are Ameliorated by Pharmacologic Activation of Nrf2 (NF-E2 p45-Related Factor 2).","date":"2017","source":"Cellular and molecular gastroenterology and hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/29552625","citation_count":173,"is_preprint":false},{"pmid":"23109674","id":"PMC_23109674","title":"The transcription factor NF-E2-related factor 2 (Nrf2): a protooncogene?","date":"2012","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/23109674","citation_count":159,"is_preprint":false},{"pmid":"15521073","id":"PMC_15521073","title":"Transcriptional regulation of thioredoxin reductase 1 expression by cadmium in vascular endothelial cells: role of NF-E2-related factor-2.","date":"2005","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/15521073","citation_count":159,"is_preprint":false},{"pmid":"22312014","id":"PMC_22312014","title":"Activation of mitochondrial biogenesis by heme oxygenase-1-mediated NF-E2-related factor-2 induction rescues mice from lethal Staphylococcus aureus sepsis.","date":"2012","source":"American journal of respiratory and critical care medicine","url":"https://pubmed.ncbi.nlm.nih.gov/22312014","citation_count":158,"is_preprint":false},{"pmid":"21355597","id":"PMC_21355597","title":"Pterostilbene is more potent than resveratrol in preventing azoxymethane (AOM)-induced colon tumorigenesis via activation of the NF-E2-related factor 2 (Nrf2)-mediated antioxidant signaling pathway.","date":"2011","source":"Journal of agricultural and food chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/21355597","citation_count":152,"is_preprint":false},{"pmid":"21217061","id":"PMC_21217061","title":"Adaptive induction of NF-E2-related factor-2-driven antioxidant genes in endothelial cells in response to hyperglycemia.","date":"2011","source":"American journal of physiology. Heart and circulatory physiology","url":"https://pubmed.ncbi.nlm.nih.gov/21217061","citation_count":147,"is_preprint":false},{"pmid":"20947826","id":"PMC_20947826","title":"NF-E2-related factor 2 promotes atherosclerosis by effects on plasma lipoproteins and cholesterol transport that overshadow antioxidant protection.","date":"2010","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/20947826","citation_count":145,"is_preprint":false},{"pmid":"20486765","id":"PMC_20486765","title":"Regulation of NF-E2-related factor 2 signaling for cancer chemoprevention: antioxidant coupled with antiinflammatory.","date":"2010","source":"Antioxidants & redox signaling","url":"https://pubmed.ncbi.nlm.nih.gov/20486765","citation_count":144,"is_preprint":false},{"pmid":"17189831","id":"PMC_17189831","title":"Shear stress stabilizes NF-E2-related factor 2 and induces antioxidant genes in endothelial cells: role of reactive oxygen/nitrogen species.","date":"2006","source":"Free radical biology & medicine","url":"https://pubmed.ncbi.nlm.nih.gov/17189831","citation_count":141,"is_preprint":false},{"pmid":"15816842","id":"PMC_15816842","title":"Ultraviolet A irradiation induces NF-E2-related factor 2 activation in dermal fibroblasts: protective role in UVA-induced apoptosis.","date":"2005","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/15816842","citation_count":140,"is_preprint":false},{"pmid":"10942379","id":"PMC_10942379","title":"Hematopoietic-specific beta 1 tubulin participates in a pathway of platelet biogenesis dependent on the transcription factor NF-E2.","date":"2000","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/10942379","citation_count":133,"is_preprint":false},{"pmid":"16962933","id":"PMC_16962933","title":"Peroxynitrite induces HO-1 expression via PI3K/Akt-dependent activation of NF-E2-related factor 2 in PC12 cells.","date":"2006","source":"Free radical biology & medicine","url":"https://pubmed.ncbi.nlm.nih.gov/16962933","citation_count":121,"is_preprint":false},{"pmid":"22155056","id":"PMC_22155056","title":"Sulforaphane attenuates hepatic fibrosis via NF-E2-related factor 2-mediated inhibition of transforming growth factor-β/Smad signaling.","date":"2011","source":"Free radical biology & medicine","url":"https://pubmed.ncbi.nlm.nih.gov/22155056","citation_count":121,"is_preprint":false},{"pmid":"8248255","id":"PMC_8248255","title":"Isolation of cDNA encoding the human NF-E2 protein.","date":"1993","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/8248255","citation_count":117,"is_preprint":false},{"pmid":"28006954","id":"PMC_28006954","title":"The Neuroprotective Effect of Dimethyl Fumarate in an MPTP-Mouse Model of Parkinson's Disease: Involvement of Reactive Oxygen Species/Nuclear Factor-κB/Nuclear Transcription Factor Related to NF-E2.","date":"2017","source":"Antioxidants & redox signaling","url":"https://pubmed.ncbi.nlm.nih.gov/28006954","citation_count":115,"is_preprint":false},{"pmid":"15005853","id":"PMC_15005853","title":"Megakaryocyte-osteoblast interaction revealed in mice deficient in transcription factors GATA-1 and NF-E2.","date":"2003","source":"Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research","url":"https://pubmed.ncbi.nlm.nih.gov/15005853","citation_count":112,"is_preprint":false},{"pmid":"9150357","id":"PMC_9150357","title":"Human small Maf proteins form heterodimers with CNC family transcription factors and recognize the NF-E2 motif.","date":"1997","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/9150357","citation_count":102,"is_preprint":false},{"pmid":"19901266","id":"PMC_19901266","title":"NF-E2 domination over Nrf2 promotes ROS accumulation and megakaryocytic maturation.","date":"2009","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/19901266","citation_count":91,"is_preprint":false},{"pmid":"22586274","id":"PMC_22586274","title":"NF-E2-related factor 1 (Nrf1) serves as a novel regulator of hepatic lipid metabolism through regulation of the Lipin1 and PGC-1β genes.","date":"2012","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/22586274","citation_count":91,"is_preprint":false},{"pmid":"10891470","id":"PMC_10891470","title":"Direct interaction of NF-E2 with hypersensitive site 2 of the beta-globin locus control region in living cells.","date":"2000","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/10891470","citation_count":90,"is_preprint":false},{"pmid":"22174413","id":"PMC_22174413","title":"Nrf2b, novel zebrafish paralog of oxidant-responsive transcription factor NF-E2-related factor 2 (NRF2).","date":"2011","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/22174413","citation_count":89,"is_preprint":false},{"pmid":"23056222","id":"PMC_23056222","title":"Dimethylfumarate attenuates renal fibrosis via NF-E2-related factor 2-mediated inhibition of transforming growth factor-β/Smad signaling.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23056222","citation_count":89,"is_preprint":false},{"pmid":"10556187","id":"PMC_10556187","title":"Pathophysiology of thrombocytopenia and anemia in mice lacking transcription factor NF-E2.","date":"1999","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/10556187","citation_count":85,"is_preprint":false},{"pmid":"23190551","id":"PMC_23190551","title":"Anti-oxidative stress regulator NF-E2-related factor 2 mediates the adaptive induction of antioxidant and detoxifying enzymes by lipid peroxidation metabolite 4-hydroxynonenal.","date":"2012","source":"Cell & bioscience","url":"https://pubmed.ncbi.nlm.nih.gov/23190551","citation_count":81,"is_preprint":false},{"pmid":"23864927","id":"PMC_23864927","title":"Attenuation of β-amyloid-induced oxidative cell death by sulforaphane via activation of NF-E2-related factor 2.","date":"2013","source":"Oxidative medicine and cellular longevity","url":"https://pubmed.ncbi.nlm.nih.gov/23864927","citation_count":78,"is_preprint":false},{"pmid":"11154691","id":"PMC_11154691","title":"Stimulation of NF-E2 DNA binding by CREB-binding protein (CBP)-mediated acetylation.","date":"2001","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11154691","citation_count":78,"is_preprint":false},{"pmid":"28411267","id":"PMC_28411267","title":"NFE2 Induces miR-423-5p to Promote Gluconeogenesis and Hyperglycemia by Repressing the Hepatic FAM3A-ATP-Akt Pathway.","date":"2017","source":"Diabetes","url":"https://pubmed.ncbi.nlm.nih.gov/28411267","citation_count":77,"is_preprint":false},{"pmid":"12907454","id":"PMC_12907454","title":"A role for Rab27b in NF-E2-dependent pathways of platelet formation.","date":"2003","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/12907454","citation_count":77,"is_preprint":false},{"pmid":"9312024","id":"PMC_9312024","title":"p45 NF-E2 regulates expression of thromboxane synthase in megakaryocytes.","date":"1997","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/9312024","citation_count":76,"is_preprint":false},{"pmid":"9675875","id":"PMC_9675875","title":"The NF-E2 transcription factor.","date":"1998","source":"The international journal of biochemistry & cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/9675875","citation_count":74,"is_preprint":false},{"pmid":"19797052","id":"PMC_19797052","title":"Active NF-E2-related factor (Nrf2) contributes to keep endothelial NO synthase (eNOS) in the coupled state: role of reactive oxygen species (ROS), eNOS, and heme oxygenase (HO-1) levels.","date":"2009","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/19797052","citation_count":74,"is_preprint":false},{"pmid":"30342186","id":"PMC_30342186","title":"Baicalein protects human vitiligo melanocytes from oxidative stress through activation of NF-E2-related factor2 (Nrf2) signaling pathway.","date":"2018","source":"Free radical biology & medicine","url":"https://pubmed.ncbi.nlm.nih.gov/30342186","citation_count":72,"is_preprint":false},{"pmid":"20395535","id":"PMC_20395535","title":"Aryl hydrocarbon receptor and NF-E2-related factor 2 are key regulators of human MRP4 expression.","date":"2010","source":"American journal of physiology. Gastrointestinal and liver physiology","url":"https://pubmed.ncbi.nlm.nih.gov/20395535","citation_count":72,"is_preprint":false},{"pmid":"22231305","id":"PMC_22231305","title":"A novel murine model of myeloproliferative disorders generated by overexpression of the transcription factor NF-E2.","date":"2012","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/22231305","citation_count":71,"is_preprint":false},{"pmid":"10613901","id":"PMC_10613901","title":"Primary megakaryocytes reveal a role for transcription factor NF-E2 in integrin alpha IIb beta 3 signaling.","date":"1999","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/10613901","citation_count":70,"is_preprint":false},{"pmid":"23589569","id":"PMC_23589569","title":"MPN patients harbor recurrent truncating mutations in transcription factor NF-E2.","date":"2013","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/23589569","citation_count":67,"is_preprint":false},{"pmid":"23403272","id":"PMC_23403272","title":"Paeoniflorin protects human EA.hy926 endothelial cells against gamma-radiation induced oxidative injury by activating the NF-E2-related factor 2/heme oxygenase-1 pathway.","date":"2013","source":"Toxicology letters","url":"https://pubmed.ncbi.nlm.nih.gov/23403272","citation_count":67,"is_preprint":false},{"pmid":"9478996","id":"PMC_9478996","title":"Regulation of NF-E2 activity in erythroleukemia cell differentiation.","date":"1998","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9478996","citation_count":66,"is_preprint":false},{"pmid":"28505160","id":"PMC_28505160","title":"Role of NF-E2 related factor 2 (Nrf2) on chemotherapy resistance in acute myeloid leukemia (AML) and the effect of pharmacological inhibition of Nrf2.","date":"2017","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/28505160","citation_count":66,"is_preprint":false},{"pmid":"20427290","id":"PMC_20427290","title":"CR6-interacting factor 1 (CRIF1) regulates NF-E2-related factor 2 (NRF2) protein stability by proteasome-mediated degradation.","date":"2010","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/20427290","citation_count":66,"is_preprint":false},{"pmid":"26773873","id":"PMC_26773873","title":"The novel triterpenoid RTA 408 protects human retinal pigment epithelial cells against H2O2-induced cell injury via NF-E2-related factor 2 (Nrf2) activation.","date":"2015","source":"Redox biology","url":"https://pubmed.ncbi.nlm.nih.gov/26773873","citation_count":65,"is_preprint":false},{"pmid":"22311972","id":"PMC_22311972","title":"Loss of transcription factor nuclear factor-erythroid 2 (NF-E2) p45-related factor-2 (Nrf2) leads to dysregulation of immune functions, redox homeostasis, and intracellular signaling in dendritic cells.","date":"2012","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/22311972","citation_count":63,"is_preprint":false},{"pmid":"17428799","id":"PMC_17428799","title":"Beta-globin active chromatin Hub formation in differentiating erythroid cells and in p45 NF-E2 knock-out mice.","date":"2007","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17428799","citation_count":60,"is_preprint":false},{"pmid":"17151289","id":"PMC_17151289","title":"Hepatic ischemia-reperfusion induces renal heme oxygenase-1 via NF-E2-related factor 2 in rats and mice.","date":"2006","source":"Molecular pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/17151289","citation_count":59,"is_preprint":false},{"pmid":"7726861","id":"PMC_7726861","title":"cDNA cloning of murine Nrf 2 gene, coding for a p45 NF-E2 related transcription factor.","date":"1995","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/7726861","citation_count":59,"is_preprint":false},{"pmid":"23043106","id":"PMC_23043106","title":"Laminar flow activation of ERK5 protein in vascular endothelium leads to atheroprotective effect via NF-E2-related factor 2 (Nrf2) activation.","date":"2012","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/23043106","citation_count":59,"is_preprint":false},{"pmid":"8423810","id":"PMC_8423810","title":"Enhancer-dependent transcription of the epsilon-globin promoter requires promoter-bound GATA-1 and enhancer-bound AP-1/NF-E2.","date":"1993","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/8423810","citation_count":58,"is_preprint":false},{"pmid":"9516460","id":"PMC_9516460","title":"Characterization of the hematopoietic transcription factor NF-E2 in primary murine megakaryocytes.","date":"1998","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9516460","citation_count":56,"is_preprint":false},{"pmid":"17467702","id":"PMC_17467702","title":"Triphlorethol-A induces heme oxygenase-1 via activation of ERK and NF-E2 related factor 2 transcription factor.","date":"2007","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/17467702","citation_count":56,"is_preprint":false},{"pmid":"9292514","id":"PMC_9292514","title":"Regulation of the serum concentration of thrombopoietin in thrombocytopenic NF-E2 knockout mice.","date":"1997","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/9292514","citation_count":56,"is_preprint":false},{"pmid":"16951152","id":"PMC_16951152","title":"Low and high dose UVB regulation of transcription factor NF-E2-related factor 2.","date":"2006","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/16951152","citation_count":53,"is_preprint":false},{"pmid":"28224478","id":"PMC_28224478","title":"Targeting the NF-E2-Related Factor 2 Pathway: a Novel Strategy for Traumatic Brain Injury.","date":"2017","source":"Molecular neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/28224478","citation_count":51,"is_preprint":false},{"pmid":"7868116","id":"PMC_7868116","title":"Chromosomal localization of the human NF-E2 family of bZIP transcription factors by fluorescence in situ hybridization.","date":"1995","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/7868116","citation_count":51,"is_preprint":false},{"pmid":"21447442","id":"PMC_21447442","title":"Epigallocatechin-gallate stimulates NF-E2-related factor and heme oxygenase-1 via caveolin-1 displacement.","date":"2011","source":"The Journal of nutritional biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/21447442","citation_count":50,"is_preprint":false},{"pmid":"18537816","id":"PMC_18537816","title":"The susceptibility to vitiligo is associated with NF-E2-related factor2 (Nrf2) gene polymorphisms: a study on Chinese Han population.","date":"2008","source":"Experimental dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/18537816","citation_count":50,"is_preprint":false},{"pmid":"10510468","id":"PMC_10510468","title":"Identification of NRF2, a member of the NF-E2 family of transcription factors, as a substrate for caspase-3(-like) proteases.","date":"1999","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/10510468","citation_count":50,"is_preprint":false},{"pmid":"26187356","id":"PMC_26187356","title":"Dipeptidyl peptidase-4 inhibition by gemigliptin prevents abnormal vascular remodeling via NF-E2-related factor 2 activation.","date":"2015","source":"Vascular pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/26187356","citation_count":49,"is_preprint":false},{"pmid":"20339092","id":"PMC_20339092","title":"AML1 is overexpressed in patients with myeloproliferative neoplasms and mediates JAK2V617F-independent overexpression of NF-E2.","date":"2010","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/20339092","citation_count":48,"is_preprint":false},{"pmid":"17676812","id":"PMC_17676812","title":"NF-E2 related factor 2 activation and heme oxygenase-1 induction by tert-butylhydroquinone protect against deltamethrin-mediated oxidative stress in PC12 cells.","date":"2007","source":"Chemical research in toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/17676812","citation_count":47,"is_preprint":false},{"pmid":"25721735","id":"PMC_25721735","title":"Regulation and function of the NFE2 transcription factor in hematopoietic and non-hematopoietic cells.","date":"2015","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/25721735","citation_count":45,"is_preprint":false},{"pmid":"24298298","id":"PMC_24298298","title":"Developmental expression of the Nfe2-related factor (Nrf) transcription factor family in the zebrafish, Danio rerio.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24298298","citation_count":45,"is_preprint":false},{"pmid":"23645672","id":"PMC_23645672","title":"Seven in absentia homolog 2 (Siah2) protein is a regulator of NF-E2-related factor 2 (Nrf2).","date":"2013","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/23645672","citation_count":45,"is_preprint":false},{"pmid":"26116522","id":"PMC_26116522","title":"Tanshinone IIA protects dopaminergic neurons against 6-hydroxydopamine-induced neurotoxicity through miR-153/NF-E2-related factor 2/antioxidant response element signaling pathway.","date":"2015","source":"Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/26116522","citation_count":43,"is_preprint":false},{"pmid":"29742982","id":"PMC_29742982","title":"NFE2-Related Transcription Factor 2 Coordinates Antioxidant Defense with Thyroglobulin Production and Iodination in the Thyroid Gland.","date":"2018","source":"Thyroid : official journal of the American Thyroid Association","url":"https://pubmed.ncbi.nlm.nih.gov/29742982","citation_count":42,"is_preprint":false},{"pmid":"35204312","id":"PMC_35204312","title":"The Effects of Nuclear Factor Erythroid 2 (NFE2)-Related Factor 2 (Nrf2) Activation in Preclinical Models of Peripheral Neuropathic Pain.","date":"2022","source":"Antioxidants (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/35204312","citation_count":41,"is_preprint":false},{"pmid":"35212366","id":"PMC_35212366","title":"Characterisation of the Circulating Transcriptomic Landscape in Inflammatory Bowel Disease Provides Evidence for Dysregulation of Multiple Transcription Factors Including NFE2, SPI1, CEBPB, and IRF2.","date":"2022","source":"Journal of Crohn's & colitis","url":"https://pubmed.ncbi.nlm.nih.gov/35212366","citation_count":41,"is_preprint":false},{"pmid":"23526214","id":"PMC_23526214","title":"Role of migratory inhibition factor in age-related susceptibility to radiation lung injury via NF-E2-related factor-2 and antioxidant regulation.","date":"2013","source":"American journal of respiratory cell and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/23526214","citation_count":41,"is_preprint":false},{"pmid":"28815354","id":"PMC_28815354","title":"NF-E2-Related Factor 2 Suppresses Intestinal Fibrosis by Inhibiting Reactive Oxygen Species-Dependent TGF-β1/SMADs Pathway.","date":"2017","source":"Digestive diseases and sciences","url":"https://pubmed.ncbi.nlm.nih.gov/28815354","citation_count":40,"is_preprint":false},{"pmid":"23673813","id":"PMC_23673813","title":"Knockdown of NF-E2-related factor 2 inhibits the proliferation and growth of U251MG human glioma cells in a mouse xenograft model.","date":"2013","source":"Oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/23673813","citation_count":40,"is_preprint":false},{"pmid":"25041126","id":"PMC_25041126","title":"Transcription factor NF-E2-related factor 1 impairs glucose metabolism in mice.","date":"2014","source":"Genes to cells : devoted to molecular & cellular mechanisms","url":"https://pubmed.ncbi.nlm.nih.gov/25041126","citation_count":38,"is_preprint":false},{"pmid":"29519804","id":"PMC_29519804","title":"Epigenetic regulation of NFE2 overexpression in myeloproliferative neoplasms.","date":"2018","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/29519804","citation_count":37,"is_preprint":false},{"pmid":"19430250","id":"PMC_19430250","title":"The expression of NF-E2-related factor 2 in the rat brain after traumatic brain injury.","date":"2009","source":"The Journal of trauma","url":"https://pubmed.ncbi.nlm.nih.gov/19430250","citation_count":35,"is_preprint":false},{"pmid":"23284002","id":"PMC_23284002","title":"Trichostatin A inhibits transforming growth factor-β-induced reactive oxygen species accumulation and myofibroblast differentiation via enhanced NF-E2-related factor 2-antioxidant response element signaling.","date":"2013","source":"Molecular pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/23284002","citation_count":35,"is_preprint":false},{"pmid":"22579713","id":"PMC_22579713","title":"The HDAC inhibitor Givinostat modulates the hematopoietic transcription factors NFE2 and C-MYB in JAK2(V617F) myeloproliferative neoplasm cells.","date":"2012","source":"Experimental hematology","url":"https://pubmed.ncbi.nlm.nih.gov/22579713","citation_count":33,"is_preprint":false},{"pmid":"24383889","id":"PMC_24383889","title":"Rho kinase inhibition drives megakaryocyte polyploidization and proplatelet formation through MYC and NFE2 downregulation.","date":"2014","source":"British journal of haematology","url":"https://pubmed.ncbi.nlm.nih.gov/24383889","citation_count":33,"is_preprint":false},{"pmid":"30755419","id":"PMC_30755419","title":"Altered NFE2 activity predisposes to leukemic transformation and myelosarcoma with AML-specific aberrations.","date":"2019","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/30755419","citation_count":32,"is_preprint":false},{"pmid":"10498903","id":"PMC_10498903","title":"Distinction between AP1 and NF-E2 factor-binding at specific chromatin regions in mammalian cells.","date":"1999","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/10498903","citation_count":31,"is_preprint":false},{"pmid":"29427626","id":"PMC_29427626","title":"Leptin induces SIRT1 expression through activation of NF-E2-related factor 2: Implications for obesity-associated colon carcinogenesis.","date":"2018","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/29427626","citation_count":30,"is_preprint":false},{"pmid":"27457419","id":"PMC_27457419","title":"NF-E2, FLI1 and RUNX1 collaborate at areas of dynamic chromatin to activate transcription in mature mouse megakaryocytes.","date":"2016","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/27457419","citation_count":29,"is_preprint":false},{"pmid":"22649188","id":"PMC_22649188","title":"Elevated hepatic iron activates NF-E2-related factor 2-regulated pathway in a dietary iron overload mouse model.","date":"2012","source":"Toxicological sciences : an official journal of the Society of Toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/22649188","citation_count":28,"is_preprint":false},{"pmid":"17923245","id":"PMC_17923245","title":"NF-E2-mediated enhancement of megakaryocytic differentiation and platelet production in vitro and in vivo.","date":"2007","source":"Experimental hematology","url":"https://pubmed.ncbi.nlm.nih.gov/17923245","citation_count":27,"is_preprint":false},{"pmid":"9009092","id":"PMC_9009092","title":"NF-E2p18/mafK is required in DMSO-induced differentiation of Friend erythroleukemia cells by enhancing NF-E2 activity.","date":"1997","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/9009092","citation_count":26,"is_preprint":false},{"pmid":"11318614","id":"PMC_11318614","title":"Human ITCH is a coregulator of the hematopoietic transcription factor NF-E2.","date":"2001","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/11318614","citation_count":25,"is_preprint":false},{"pmid":"27246794","id":"PMC_27246794","title":"Accumulation of phosphorylated p62 is associated with NF-E2-related factor 2 activation in hepatocellular carcinoma.","date":"2016","source":"Journal of hepato-biliary-pancreatic sciences","url":"https://pubmed.ncbi.nlm.nih.gov/27246794","citation_count":25,"is_preprint":false},{"pmid":"7724591","id":"PMC_7724591","title":"Isolation of a differentially regulated splicing isoform of human NF-E2.","date":"1995","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/7724591","citation_count":25,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":52772,"output_tokens":6285,"usd":0.126296},"stage2":{"model":"claude-opus-4-6","input_tokens":9964,"output_tokens":3418,"usd":0.202905},"total_usd":0.329201,"stage1_batch_id":"msgbatch_012ZiiCUBfB62NCTQd4Bk1Jo","stage2_batch_id":"msgbatch_01Xuqq9aUHoQouS7UVGZNStZ","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1993,\n      \"finding\": \"NFE2 (p45 NF-E2) is a hematopoietic-specific basic-leucine zipper protein that dimerizes with a ubiquitous partner (p18) to form the functional NF-E2 heterodimer, which binds AP-1-like recognition sites in globin locus control regions.\",\n      \"method\": \"cDNA cloning, protein purification, DNA binding assays\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — original cloning with biochemical characterization, foundational paper with 598 citations\",\n      \"pmids\": [\"8469283\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"The ubiquitous p18 subunit of NF-E2 is a small basic-leucine zipper protein related to the v-maf oncogene, and forms the obligate heterodimeric partner with p45 NF-E2 for DNA binding.\",\n      \"method\": \"Protein purification, cDNA cloning, sequence analysis\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — protein purification and cloning with 250 citations, replicated by other labs\",\n      \"pmids\": [\"8265578\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"Small Maf proteins (MafF, MafG, MafK) directly control the DNA-binding properties of p45 NF-E2 through heterodimeric association; Maf homodimers act as negative regulators while p45-Maf heterodimers support active transcription, establishing that small Maf proteins are the second constituent chain of NF-E2.\",\n      \"method\": \"In vitro dimerization assays, transcription assays in erythroid cells, transfection experiments\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstituted heterodimer activity in vitro and in vivo, replicated across labs, 417 citations\",\n      \"pmids\": [\"8107826\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"NF-E2 binding to AP-1/NF-E2 sites in the beta-globin locus control region enhancer is required for enhancer-dependent transcription of epsilon-globin, while GATA-1 binding at the promoter mediates the enhancer-promoter interaction.\",\n      \"method\": \"In vitro transcription, site-directed mutagenesis of NF-E2 sites\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro transcription with mutagenesis, multiple orthogonal approaches\",\n      \"pmids\": [\"8423810\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"Small Maf proteins can also heterodimerize with Fos, and Fos-small Maf heterodimers cannot activate NF-E2 site-dependent transcription, suggesting competitive regulation of erythroid gene expression among Fos, NF-E2 p45, and small Maf proteins.\",\n      \"method\": \"In vitro DNA binding, co-immunoprecipitation, transfection assays\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — multiple in vitro and in vivo assays, replicated interaction data\",\n      \"pmids\": [\"7891713\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"Bach1 and Bach2, novel BTB-bZip transcription factors, heterodimerize with MafK and bind NF-E2 sites in vitro; they function as transcriptional repressors in fibroblasts but Bach1 acts as an activator in erythroid cells, competing with p45 NF-E2 for MafK binding.\",\n      \"method\": \"Yeast two-hybrid screen, in vitro DNA binding, transfection assays\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — yeast two-hybrid plus in vitro binding plus functional assays, 567 citations\",\n      \"pmids\": [\"8887638\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"p45 NF-E2 directly regulates the thromboxane synthase (TXS) gene in megakaryocytes through functional NF-E2 binding sites in its promoter and an intronic chromatin-dependent enhancer; p45-null megakaryocytes lack TXS mRNA.\",\n      \"method\": \"In vivo chromatin immunoprecipitation/immunoselection, promoter/enhancer reporter assays, p45-null mouse analysis\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — in vivo binding plus reporter assays plus genetic knockout validation\",\n      \"pmids\": [\"9312024\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"In primary megakaryocytes, p45 NF-E2 is the only large subunit that dimerizes with small Maf proteins; MafG and/or MafF predominate in megakaryocytes (unlike MafK in erythroid cells), and the NF-E2 complex preferentially binds an asymmetric AP-1-related motif.\",\n      \"method\": \"Nuclear extract preparation, EMSA, biochemical characterization of primary megakaryocytes\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — biochemical analysis of primary cells with multiple binding assays\",\n      \"pmids\": [\"9516460\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"NF-E2 activity (both DNA binding and transactivation) is upregulated during erythroid differentiation in erythroleukemia cells via serine/threonine phosphorylation through the Ras-Raf-MAP kinase cascade; MafK homodimers suppress transcription by direct inhibition in addition to DNA site competition.\",\n      \"method\": \"Kinase inhibitor experiments, domain analysis, transient transfection assays, DMSO-induced differentiation\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — functional assays with pharmacological inhibitors, single lab\",\n      \"pmids\": [\"9478996\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"NF-E2-deficient megakaryocytes fail to activate alphaIIbbeta3 integrin in response to agonists despite normal surface expression, establishing that NF-E2 controls signaling pathways required for integrin activation that mature late in megakaryocyte development.\",\n      \"method\": \"Primary megakaryocytes from NF-E2 knockout mice, fibrinogen binding assays, Sindbis virus-mediated gene expression\",\n      \"journal\": \"The Journal of cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic knockout with specific phenotypic readout and complementation, replicated with pharmacological tools\",\n      \"pmids\": [\"10613901\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"Mice lacking p45 NF-E2 have profound thrombocytopenia due to late arrest in megakaryocyte differentiation with reduced proliferation potential, and also develop erythroid abnormalities including anisocytosis, hypochromia, and small red blood cell fragments, establishing NF-E2 as required for both megakaryocyte and erythrocyte maturation.\",\n      \"method\": \"NF-E2 knockout mice, splenectomy, bone marrow transplantation, hematopoietic cell transfer\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple genetic and transplantation experiments with defined phenotypic readouts\",\n      \"pmids\": [\"10556187\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"NF-E2 binds directly and specifically to the tandem Maf recognition elements of hypersensitive site 2 (HS2) of the beta-globin locus control region in living erythroleukemia cells and fetal liver, dependent on p45 and intact MAREs.\",\n      \"method\": \"Chromatin immunoprecipitation assay in intact cells\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — ChIP in primary cells and cell lines with p45-null controls\",\n      \"pmids\": [\"10891470\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"NF-E2 transcriptionally regulates beta1 tubulin expression in megakaryocytes; NF-E2-deficient megakaryocytes lack beta1 tubulin mRNA/protein, and restoring NF-E2 rescues beta1 tubulin expression, linking NF-E2 to microtubule-based proplatelet formation.\",\n      \"method\": \"mRNA subtraction between NF-E2-null and wild-type megakaryocytes, NF-E2 rescue experiments in primary cells and cell lines\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic loss-of-function with target gene identification and rescue, 133 citations\",\n      \"pmids\": [\"10942379\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"CBP acetyltransferase physically interacts with both p45 NF-E2 and MafG subunits; CBP acetylates MafG predominantly in the basic region, and MafG acetylation augments NF-E2 DNA binding activity; mutations at major acetylation sites markedly reduce DNA binding and transcriptional activation.\",\n      \"method\": \"Co-immunoprecipitation in vitro and in vivo, acetyltransferase assays, mutagenesis, transfection reporter assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro enzymatic assay with mutagenesis and in vivo validation\",\n      \"pmids\": [\"11154691\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Human ITCH protein interacts with p45 NF-E2 (identified by yeast two-hybrid) and functions as a transcriptional corepressor of NF-E2 in transfection experiments.\",\n      \"method\": \"Yeast two-hybrid, transfection corepressor assays\",\n      \"journal\": \"Genomics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — yeast two-hybrid plus transfection assay, single lab, limited follow-up\",\n      \"pmids\": [\"11318614\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"NF-E2 transcriptionally regulates Rab27b expression in megakaryocytes; ChIP demonstrates NF-E2 recruitment to the Rab27B promoter; Rab27b localizes to alpha and dense granules, and inhibition of Rab27 function causes severe defects in proplatelet formation.\",\n      \"method\": \"Chromatin immunoprecipitation, subcellular localization (immunofluorescence), dominant-negative inhibition in primary megakaryocytes\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — ChIP plus localization plus functional assay in primary cells\",\n      \"pmids\": [\"12907454\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Heme induces displacement of Bach1 from MafK-occupied ho-1 enhancers and subsequent Nrf2 binding, accompanied by de novo histone H3 hyperacetylation and hypermethylation in the transcribed region, establishing heme as a signaling molecule that drives partner exchange in the small Maf transcription factor network.\",\n      \"method\": \"Chromatin immunoprecipitation assays in NIH 3T3 cells, histone modification analysis\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — ChIP with multiple histone marks, replicated at both ho-1 and beta-globin loci, 311 citations\",\n      \"pmids\": [\"14747657\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"In differentiating erythroid cells, formation of the beta-globin active chromatin hub (ACH) requires GATA-1 and EKLF but not p45 NF-E2; NF-E2 is dispensable for ACH formation as shown in p45 NF-E2 knockout mice.\",\n      \"method\": \"Chromosome conformation capture (3C), knock-out mouse analysis, erythroid differentiation model\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic knockout with specific chromatin structure readout using 3C\",\n      \"pmids\": [\"17428799\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"In megakaryocytes, p45 NF-E2 dominates over Nrf2 at shared cytoprotective gene targets, acting as a less efficacious activator to maintain moderate expression, thereby promoting ROS accumulation that in turn enhances platelet gene expression and megakaryocytic maturation.\",\n      \"method\": \"Comprehensive gene expression profiling in wild-type and p45-null megakaryocytes, competition assays between p45 and Nrf2\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genome-wide expression profiling with genetic null models plus functional follow-up\",\n      \"pmids\": [\"19901266\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"AML1/RUNX1 directly binds the NF-E2 promoter in vivo and transcriptionally activates NF-E2 expression; AML1 binding is increased in granulocytes from polycythemia vera patients; RNAi knockdown of AML1 or its partner CBF-beta decreases NF-E2 expression, identifying NF-E2 as a novel AML1 target gene.\",\n      \"method\": \"Chromatin immunoprecipitation, RNAi knockdown, promoter characterization, NF-E2 promoter-reporter assays\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — ChIP in primary patient cells plus RNAi with multiple approaches\",\n      \"pmids\": [\"20339092\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Overexpression of NF-E2 in hematopoietic cells causes myeloproliferative neoplasm features including thrombocytosis and leukocytosis; NF-E2 transgenic mice show hypoacetylation of histone H3, and HDAC inhibitor treatment restores H3 acetylation, decreases NF-E2 expression, and normalizes platelet numbers.\",\n      \"method\": \"NF-E2 transgenic mouse model, bone marrow transplantation, histone modification analysis, HDAC inhibitor treatment\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — transgenic mouse model with transplantation and pharmacological rescue, 71 citations\",\n      \"pmids\": [\"22231305\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Acquired truncating insertion/deletion mutations in NFE2 found in MPN patients produce truncated NF-E2 proteins that enhance wild-type NF-E2 function; expression in mice causes erythrocytosis and thrombocytosis, and mutant cells acquire clonal dominance over wild-type NF-E2 cells.\",\n      \"method\": \"Mutation sequencing in MPN patients, murine model of mutant NFE2 expression, clonal analysis\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — human mutations functionally characterized in murine model with clonal analysis\",\n      \"pmids\": [\"23589569\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"NF-E2 co-occupies late-acting cis-regulatory enhancers with FLI1 and RUNX1 in terminal megakaryocyte maturation; co-occupancy by NF-E2 with either RUNX1 or FLI1 gives the highest H3K4me2 histone signals and correlates with genes activated late in megakaryocyte differentiation responsible for platelet assembly and release.\",\n      \"method\": \"ChIP-seq for NF-E2, FLI1, RUNX1, and histone marks; genome-wide chromatin dynamics analysis in primary megakaryocytes\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genome-wide ChIP-seq in primary cells with genetic validation using Nfe2-null\",\n      \"pmids\": [\"27457419\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"NFE2 directly induces miR-423-5p expression to repress the FAM3A-ATP-Akt pathway in hepatocytes, promoting gluconeogenesis, lipid deposition, and hyperglycemia; hepatic NFE2 overexpression phenocopies this pathway activation in normal mice.\",\n      \"method\": \"miRNA target validation, reporter assays, NFE2 overexpression in mouse liver, siRNA knockdown\",\n      \"journal\": \"Diabetes\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vivo overexpression with mechanistic pathway tracing, single lab\",\n      \"pmids\": [\"28411267\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Histone demethylase JMJD1C is a novel NFE2 target gene; JMJD1C in turn binds the NFE2 promoter, decreasing H3K9me2 levels and HP1α binding to autoregulate NFE2 expression; separately, JAK2V617F-driven H3Y41 phosphorylation also inhibits HP1α binding to activate NFE2 expression.\",\n      \"method\": \"ChIP at JMJD1C and NFE2 promoters, histone modification analysis, decitabine treatment in JAK2V617F cell lines\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — ChIP with multiple histone marks plus pharmacological and genetic perturbation, replicated in patient samples\",\n      \"pmids\": [\"29519804\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"NFE2 mutations in AML patients and in MPN patients predispose to leukemic transformation; NF-E2 mutant mice develop myelosarcomas and AML acquiring secondary mutations including trisomy 8 equivalent, chromosome 5q deletions, and Trp53 mutations.\",\n      \"method\": \"Longitudinal mouse modeling of NFE2 mutations, cytogenetic and mutation analysis of transformed tumors\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vivo mouse model with defined secondary lesions, validated in human AML samples\",\n      \"pmids\": [\"30755419\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"Two alternatively spliced isoforms of NF-E2 (aNF-E2 and fNF-E2) differ in their 5' untranslated regions and are expressed in different ratios during development (fNF-E2 predominates in fetal liver; aNF-E2 in adult bone marrow), though both produce the same protein.\",\n      \"method\": \"cDNA library screening, RT-PCR, developmental expression analysis\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — cloning and expression pattern, single lab\",\n      \"pmids\": [\"7724591\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Mice deficient in NF-E2 (or GATA-1) show 200–300% increases in bone volume and formation; osteoblast proliferation increases up to 6-fold when cultured with NF-E2-deficient megakaryocytes by a mechanism requiring cell-to-cell contact, revealing a megakaryocyte-osteoblast interaction dependent on the excess immature megakaryocytes produced in NF-E2 null mice.\",\n      \"method\": \"Histomorphometry, microCT, in vitro co-culture of osteoblasts with NF-E2-null megakaryocytes\",\n      \"journal\": \"Journal of bone and mineral research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic model with in vitro co-culture phenotype, but mechanistic details indirect\",\n      \"pmids\": [\"15005853\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Rho kinase (ROCK) inhibition drives megakaryocyte polyploidization and proplatelet formation, coinciding with downregulation of NFE2 expression in mature megakaryocytes, suggesting a model where ROCK inhibition drives late megakaryocyte maturation through NFE2 downregulation.\",\n      \"method\": \"ROCK inhibitor treatment of cord blood-derived megakaryocytes, proplatelet formation assay, gene expression analysis\",\n      \"journal\": \"British journal of haematology\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — pharmacological inhibitor study with correlative NFE2 expression change, no direct NFE2 rescue\",\n      \"pmids\": [\"24383889\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"NFE2 (p45 NF-E2) is a hematopoietic-specific CNC-family basic-leucine zipper transcription factor that forms obligate heterodimers with small Maf proteins (MafF/G/K) — whose DNA-binding activity is augmented by CBP-mediated acetylation of MafG — to bind NF-E2/AP-1-like sites in the locus control regions of globin genes and in promoters/enhancers of megakaryocyte genes including thromboxane synthase, beta1 tubulin, and Rab27b, thereby driving erythroid differentiation and being essential for proplatelet formation and platelet biogenesis; NFE2 activity is co-regulated by competing partners (Bach1, Fos-Maf) and upstream regulators including AML1/RUNX1 (which drives NFE2 transcription) and JMJD1C (which participates in an NFE2 autoregulatory loop via H3K9 demethylation), and overexpression or gain-of-function mutations in NFE2 cause myeloproliferative neoplasms with predisposition to leukemic transformation.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"NFE2 (p45 NF-E2) is a hematopoietic-specific CNC-family basic-leucine zipper transcription factor essential for terminal megakaryocyte maturation, proplatelet formation, and erythroid differentiation. It forms obligate heterodimers with small Maf proteins (MafF, MafG, MafK) to bind NF-E2/AP-1-like recognition elements in globin locus control regions and in megakaryocyte-specific gene promoters including thromboxane synthase, β1 tubulin, and Rab27b, with DNA-binding activity augmented by CBP-mediated acetylation of MafG [PMID:8469283, PMID:8107826, PMID:11154691, PMID:9312024, PMID:10942379, PMID:12907454]. NFE2 activity is regulated by competing partners (Bach1, Fos–Maf homodimers) for small Maf binding, by upstream transcriptional activation through AML1/RUNX1, and by an autoregulatory loop involving the histone demethylase JMJD1C that modulates H3K9 methylation at the NFE2 promoter [PMID:8887638, PMID:7891713, PMID:20339092, PMID:29519804]. Overexpression or acquired truncating mutations of NFE2 cause myeloproliferative neoplasms with thrombocytosis and predisposition to leukemic transformation [PMID:22231305, PMID:23589569, PMID:30755419].\",\n  \"teleology\": [\n    {\n      \"year\": 1993,\n      \"claim\": \"Identification of NFE2 as a hematopoietic bZIP factor that heterodimerizes with a small subunit to bind AP-1-like sites in globin LCRs established the molecular identity of the NF-E2 complex and its role in erythroid gene regulation.\",\n      \"evidence\": \"cDNA cloning, protein purification, DNA-binding assays, and in vitro transcription with NF-E2-site mutagenesis\",\n      \"pmids\": [\"8469283\", \"8265578\", \"8423810\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the small subunit not yet resolved as Maf family\", \"In vivo target gene specificity unknown\"]\n    },\n    {\n      \"year\": 1994,\n      \"claim\": \"Demonstrating that small Maf proteins (MafF/G/K) are the obligate heterodimeric partners of p45 resolved the composition of functional NF-E2 and revealed that Maf homodimers act as repressors, establishing a competitive dimerization paradigm.\",\n      \"evidence\": \"In vitro dimerization and transcription assays in erythroid cells\",\n      \"pmids\": [\"8107826\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative contributions of individual small Mafs in different lineages unknown\", \"In vivo stoichiometry unresolved\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"Discovery that Bach1, Fos, and other bZIP factors compete with p45 for small Maf binding at NF-E2 sites established a partner-exchange regulatory network controlling erythroid and stress-response gene expression.\",\n      \"evidence\": \"Yeast two-hybrid, in vitro DNA binding, transfection assays, and later heme-induced ChIP showing Bach1 displacement\",\n      \"pmids\": [\"7891713\", \"8887638\", \"14747657\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative affinities and kinetics of partner exchange in vivo not quantified\", \"Signals governing Bach1–NF-E2 switching beyond heme not fully defined\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Analysis of NF-E2-knockout mice revealed that p45 is essential for platelet biogenesis and erythrocyte maturation, with thrombocytopenia resulting from a late block in megakaryocyte differentiation and failure of integrin αIIbβ3 activation.\",\n      \"evidence\": \"NF-E2-null mice with bone marrow transplantation, fibrinogen binding, and complementation assays\",\n      \"pmids\": [\"10556187\", \"10613901\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full repertoire of NF-E2-dependent megakaryocyte genes not catalogued\", \"Mechanism of integrin activation defect unclear\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Identification of β1 tubulin and confirmation of NF-E2 occupancy at the β-globin LCR HS2 in living cells defined direct transcriptional targets linking NF-E2 to cytoskeletal proplatelet formation and globin regulation.\",\n      \"evidence\": \"ChIP in erythroleukemia and fetal liver cells; mRNA subtraction between NF-E2-null and WT megakaryocytes with rescue\",\n      \"pmids\": [\"10891470\", \"10942379\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether NF-E2 is required for LCR-mediated chromatin looping not resolved\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"CBP-mediated acetylation of MafG in its basic region augments NF-E2 DNA binding and transactivation, establishing post-translational modification of the heterodimeric partner as a regulatory mechanism.\",\n      \"evidence\": \"In vitro acetyltransferase assays, co-immunoprecipitation, mutagenesis, transfection reporter assays\",\n      \"pmids\": [\"11154691\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo dynamics of MafG acetylation during differentiation unknown\", \"Other acetyltransferases not tested\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"NF-E2 directly activates Rab27b in megakaryocytes, linking NF-E2 to granule transport and proplatelet formation through a vesicle-trafficking effector.\",\n      \"evidence\": \"ChIP at Rab27b promoter, immunofluorescence localization, dominant-negative Rab27 inhibition in primary megakaryocytes\",\n      \"pmids\": [\"12907454\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full set of granule-trafficking genes controlled by NF-E2 not defined\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Chromosome conformation capture in NF-E2-null erythroid cells demonstrated that NF-E2 is dispensable for β-globin active chromatin hub formation, refining NF-E2's role to transcriptional activation rather than long-range chromatin looping.\",\n      \"evidence\": \"3C assays in NF-E2-knockout mouse erythroid cells\",\n      \"pmids\": [\"17428799\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Precise step at which NF-E2 acts after chromatin hub assembly not defined\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Identifying NFE2 as a direct transcriptional target of AML1/RUNX1 placed NFE2 downstream of a key megakaryocyte master regulator and explained elevated NFE2 in polycythemia vera.\",\n      \"evidence\": \"ChIP at NFE2 promoter, RNAi knockdown of AML1/CBFβ, promoter-reporter assays in patient granulocytes\",\n      \"pmids\": [\"20339092\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether RUNX1-driven NFE2 upregulation is sufficient for MPN initiation not tested\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Transgenic overexpression of NF-E2 caused myeloproliferative neoplasm features with histone H3 hypoacetylation, reversible by HDAC inhibitors, establishing NFE2 gain-of-function as oncogenic in myeloid neoplasia.\",\n      \"evidence\": \"NF-E2 transgenic mouse model, bone marrow transplantation, histone modification analysis, HDAC inhibitor rescue\",\n      \"pmids\": [\"22231305\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct chromatin targets mediating the MPN phenotype not identified\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Acquired truncating NFE2 mutations in MPN patients produce gain-of-function proteins that enhance wild-type NF-E2 activity and confer clonal dominance, providing a genetic mechanism for disease progression.\",\n      \"evidence\": \"Patient mutation sequencing, murine expression model, clonal competition assays\",\n      \"pmids\": [\"23589569\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis for gain-of-function by truncated proteins unknown\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Genome-wide co-occupancy mapping showed NF-E2 collaborates with FLI1 and RUNX1 at late-acting megakaryocyte enhancers marked by high H3K4me2, defining the combinatorial code for terminal platelet gene activation.\",\n      \"evidence\": \"ChIP-seq for NF-E2, FLI1, RUNX1, and histone marks in primary megakaryocytes\",\n      \"pmids\": [\"27457419\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Causal hierarchy among NF-E2, FLI1, and RUNX1 at co-occupied enhancers not resolved\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Discovery of a JMJD1C–NFE2 autoregulatory loop, where NFE2 induces JMJD1C which demethylates H3K9 at the NFE2 promoter to sustain NFE2 expression, revealed an epigenetic feedforward mechanism exploited by JAK2V617F-driven MPN.\",\n      \"evidence\": \"ChIP at JMJD1C and NFE2 promoters, histone modification analysis, pharmacological perturbation in JAK2V617F cells and patient samples\",\n      \"pmids\": [\"29519804\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether disrupting the JMJD1C–NFE2 loop is therapeutically sufficient in MPN is untested\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Longitudinal modeling showed NFE2 mutations predispose to AML transformation with acquisition of secondary lesions including Trp53 loss and trisomy 8 equivalent, establishing NFE2 as a driver of leukemic evolution.\",\n      \"evidence\": \"Mouse modeling of NFE2 mutations with cytogenetic and mutation analysis of transformed tumors, validated in human AML\",\n      \"pmids\": [\"30755419\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether NFE2 mutations directly cause genomic instability or simply provide a selective advantage is unresolved\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The structural basis for how truncated NFE2 mutant proteins enhance wild-type function, the full catalog of direct NF-E2 target genes in megakaryocytes versus erythroid cells, and whether targeting the JMJD1C–NFE2 autoregulatory loop can prevent leukemic transformation remain open questions.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No crystal structure of NF-E2–Maf heterodimer available\", \"Genome-wide NF-E2 target gene sets in erythroid cells not comprehensively validated\", \"Therapeutic strategies targeting NFE2 overexpression in MPN not clinically tested\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [0, 3, 11]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [0, 3, 6, 12, 15, 22]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [0, 7, 11]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [0, 3, 6, 12, 15, 22]},\n      {\"term_id\": \"R-HSA-4839726\", \"supporting_discovery_ids\": [13, 16, 24]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [10, 12, 22]},\n      {\"term_id\": \"R-HSA-109582\", \"supporting_discovery_ids\": [9, 10, 12]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [20, 21, 25]}\n    ],\n    \"complexes\": [\n      \"NF-E2 (p45-small Maf heterodimer)\"\n    ],\n    \"partners\": [\n      \"MAFF\",\n      \"MAFG\",\n      \"MAFK\",\n      \"BACH1\",\n      \"CREBBP\",\n      \"FLI1\",\n      \"RUNX1\",\n      \"JMJD1C\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}